HOW WE CAN HELP
Our multi-disciplinary healthcare and life sciences team comprises sector specialists from all parts of the firm. Many have technical life sciences qualifications in addition to their legal expertise. This breadth of expertise means we can respond to clients’ needs across the full spectrum of healthcare and life sciences matters.
Our services
- Capital raising
- Competition
- Corporate, project finance and tax
- Cyber security
- Data and privacy
- Disputes and investigations
- Employment
- Real estate and infrastructure, including PPPs
- Intellectual property and patents
- Mergers and acquisitions
- Private equity
- Therapeutic Goods Regulation
- Technology and digital.
We provide advisory services to a diverse range of clients, including:
- Government departments, agencies and research bodies
- Healthcare service providers, including hospital and day surgery operators and pathology, imaging and other diagnostic service providers
- MedTech and digital health businesses
- Pharma and biotechs
- Private equity, venture capital and other investors
- Private health insurers
- Research institutes and clinical research organisations.
INTERNATIONAL CAPABILITIES
We advise on global transactions. We work on cross-border and international deals as Australian counsel or lead counsel advising on transactional, competition and financing issues for some of the largest global healthcare players. The matters our IP and litigation lawyers are engaged in are invariably multi-jurisdiction disputes concerning globally significant technologies. Most of our partners and many of our lawyers have also practised in other jurisdictions at top-tier overseas firms (particularly London, New York, Tokyo, Hong Kong and Singapore). We enjoy close 'best friends' relationships with the leading firms in all key foreign jurisdictions. This means we are not tied to the pre-determined connections of larger international firms but can provide seamless cross-border advice utilising the best lawyers in each jurisdiction.
In relation to the Australian aspects of Google’s acquisition of its businesses.
On the Australian aspects of its merger with Pfizer’s Upjohn division to form Viatris.
In relation to ACCC clearance for its US $7.6 billion acquisition of Bayer AG’s animal health business.
On the Australian competition aspects on their $25 billion acquisition of Nuance Communications.
On the Australian aspects of its US$63 billion acquisition by AbbVie Inc.
On the Australian competition law aspects of its US$66.8 billion merger with rival drug maker Wyeth.
On the competition aspects of its successful $560 million bid for the consumer business of Symbion Health.
In relation to claims of patent infringement by Sequenom, Inc, which offers the competing “MaterniT21” genetic test.
On its joint venture with Medibank for the delivery of the My Home Hospital program for Wellbeing SA.